Human Papillomavirus testing,
from cervical to oral and anal.
HPV is the most common sexually transmitted infection in the world. Most strains clear on their own — but persistent infection with high-risk genotypes is the leading cause of cervical, oropharyngeal and anal cancers. Knowing your status, early, changes the outcome.
Full genotyping for 14 high-risk strains
Our assay is a validated real-time PCR test that individually identifies HPV types 16 and 18 — responsible for roughly 70% of cervical cancers — and reports a pooled result for 12 additional high-risk types (31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68). You receive a clear, genotype-level report rather than a simple positive/negative.
Three anatomical sites, one molecular method
Cervical HPV
Clinician-collected liquid-based sample or validated self-collection vaginal swab. Indicated for routine screening from age 25, every 5 years when negative.
Oral HPV
Oropharyngeal rinse and gargle sample. Increasingly relevant given the rise in HPV-related throat cancers — recommended for adults with multiple oral-sex partners.
Anal HPV
Anal canal swab. Particularly recommended for men who have sex with men, people living with HIV, and anyone with a history of receptive anal intercourse.
Recommended testing windows
Screening guidelines have shifted toward HPV-first testing because PCR is more sensitive than cytology alone. Our clinical team will help match the right combination of sites and intervals to your history.
- Women aged 25–65: cervical HPV every 5 years
- After an abnormal Pap or LSIL/HSIL result: HPV genotyping
- Following a new sexual partner or known HPV exposure
- Before or during pregnancy planning
- Adults with persistent oral or throat symptoms
- Men and women with a history of receptive anal intercourse